COVID-19 Vaccine Skycovion Among Raft Of New EU Filings
EU marketing authorization applications for 12 products, including Skycovion, trastuzumab duocarmazine, alpelisib and sparsenta, are now being evaluated by the European Medicines Agency.
You may also be interested in...
Fresenius Kabi’s tocilizumab biosimilar candidate is among the latest medicines that have been submitted for review for potential pan-EU approval.
Keeping Track: Longer US FDA Reviews For Tislelizumab, Toripalimab, Olipudase; Perrigo Wants OC To Go OTC
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Polpharma Biologics has claimed the first biosimilar natalizumab filing in Europe, after the European Medicines Agency accepted the firm’s marketing authorization application for review.